Breast Cancer News
Top Stories
Raloxifene Reduces Risk Of Invasive Estrogen-Receptor Positive Breast Cancer
POSTED: June 24, 2008Women who took raloxifene were less likely to develop invasive estrogen-receptor (ER) positive breast cancer compared with women who did not, according to data from a randomized controlled trial published online June 10 in the Journal of the National Cancer Institute. The drug did not reduce the risk of non-invasive cancer or invasive ER-negative cancer...
New Australian Technology: Detecting Breast Cancer With Hair
POSTED: June 20, 2008SAN DIEGO -- The Australian company Fermiscan, who is using a US synchrotron in the development of a new breast cancer screening test through the analysis of an individual's hair, has demonstrated an accuracy rate of 69% in detecting breast cancer. A recent study published in the Journal of the American Medical Association(1) (US study), show...
Raloxifene Reduces Risk Of Invasive Estrogen-receptor Positive Breast Cancer
POSTED: June 20, 2008Women who took raloxifene were less likely to develop invasive estrogen-receptor (ER) positive breast cancer compared with women who did not, according to data from a randomized controlled trial published online June 10 in the Journal of the National Cancer Institute. The drug did not reduce the risk of non-invasive cancer or invasive ER-negative cancer...
Breast Cancer Patients With Greater Need Seek More Information Online
POSTED: June 20, 2008MADISON, Wis. -- Patients with more concerns about their breast cancer are heavier users of online information, according to a new study conducted by the University of Wisconsin-Madison Center for Excellence in Cancer Communications Research funded by the National Cancer Institute. Additionally, those in greater need were more likely to seek ...
Cancer Risk Reduced By 80% After Bariatric Surgery - Largest Reductions Seen In Breast Cancer And Colon Cancer
POSTED: June 20, 2008MONTRÉAL, QC and WASHINGTON, DC -- A new study of nearly 6,800 morbidly obese patients shows that those who had bariatric surgery reduced the risk of developing cancer by about 80 percent, with breast cancer and colon cancer showing the greatest reductions. The study was presented today here at the 25th Annual Meeting of the American Society for...
Tanespimycin Shows High Level Of Activity In Trastuzumab Resistant/Refractory Her2-positive Breast Cancer
POSTED: June 17, 2008Kosan Biosciences Incorporated announced that its lead Hsp90 inhibitor, tanespimycin, demonstrated a high level of antitumor activity in a Phase 2 trial when administered in combination with trastuzumab (Herceptin(R)) to patients with HER2-positive metastatic breast cancer whose disease had either progressed after, or did not respond to, treatment with ...
Hyperthermia Therapy Featured As A 'Powerful Tool' In Cancer Treatment By ABC Television Philadelphia Affiliate
POSTED: June 13, 2008BSD Medical Corp. announced the recent airing of a news segment titled "Putting the heat on cancer" on WPVI-TV (ABC Channel 6) in Philadelphia. The segment interviewed patients and clinicians at the Cancer Treatment Centers of America (CTCA) in Philadelphia and highlighted the important role that hyperthermia therapy can play in cancer treatment. CTCA p...
Metformin Increases Pathologic Complete Response Rates In Breast Cancer Patients With Diabetes
POSTED: June 13, 2008Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The Univers...
Paclitaxel Poliglumex OPAXIO/Capecitabine Regimen Well Tolerated And Active In Metastatic Breast Cancer
POSTED: June 13, 2008At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (OPAXIO(TM), CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC). The goals of the study were to explore the tolerability and ...
Further Clinical Testing Of BZL101 In Advanced Breast Cancer Demonstrates Favorable Efficacy And Toxicity Profiles
POSTED: June 13, 2008Bionovo Inc. announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in patients with refractory, metastatic breast cancer. The data, which were presented at the American Society of Clinical Oncology 44th Annual Meeting, showed that BZL101, at higher doses, continues to have a favorable safety and tolerability profile a...
